OxSonics was founded in 2013 to commercialise ground-breaking technological advances developed over more than ten years at the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) at the University of Oxford in the UK. BUBBL is an internationally-recognized centre of excellence in therapeutic ultrasound and drug delivery within the Oxford Institute of Biomedical Engineering.

Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran® Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.

Today, SonoTran® is being evaluated clinically and we’re working with multiple partners to tackle the toughest cancers, head on.